Differential Toxicity Profile: Tarlatamab vs Traditional Cytotoxic Therapies
Panelists discuss how tarlatamab’s toxicity profile differs from traditional cytotoxic therapies, highlighting its immune-related adverse effects such as cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome, while noting its lower risk of myelosuppression and long-term organ damage compared with chemotherapy, which tends to cause cumulative toxicities such as bone marrow suppression.
EP: 1.ES-SCLC vs LS-SCLC: Critical Differences in Disease Burden and Patient Prognosis
EP: 2.Current Treatment Paradigm: Evolution of First-Line Therapy for ES-SCLC
EP: 3.Addressing Critical Unmet Needs in ES-SCLC Patient Management
EP: 4.Emerging Clinical Trials: Novel Approaches in Second-Line ES-SCLC
EP: 5.Institutional Implementation: Setting Up Tarlatamab Administration
EP: 6.Optimizing Multidisciplinary Coordination for Successful Tarlatamab Implementation
EP: 7.Patient Selection Criteria: Identifying Appropriate Candidates for Tarlatamab
EP: 8.Tarlatamab Administration and Postinfusion Monitoring
EP: 9.Essential Patient and Caregiver Education for Tarlatamab Treatment Success
EP: 10.Neurological Toxicity Recognition: ICANS Assessment and Management
EP: 11.CRS Recognition and Intervention: Timing and Clinical Features
EP: 12.Nonimmune Adverse Effects: Managing Dysgeusia and Fatigue
EP: 13.Differential Toxicity Profile: Tarlatamab vs Traditional Cytotoxic Therapies
EP: 14.Standardized Toxicity Grading: Institutional Protocols for CRS and ICANS
Summary for Physicians:
Differential Toxicity Profile: Tarlatamab vs Traditional Cytotoxic Therapies
- Tarlatamab (immunotherapy):
- Immune-related toxicities: Includes cytokine release syndrome, immune effector cell–associated neurotoxicity syndrome, and immune-related adverse events (eg, rash, colitis)
- Less myelosuppression compared with traditional chemotherapy
- Onset of adverse effects is typically within 24 to 48 hours post infusion
- Traditional cytotoxic therapies:
- Common toxicities: Myelosuppression, nausea/vomiting, alopecia, fatigue, and mucositis
- Delayed onset of adverse effects (often seen after several cycles)
- Dose-limiting toxicities often related to bone marrow suppression
Key Differences:
- Tarlatamab may cause acute immune reactions but spares long-term organ damage compared with cytotoxic therapies.
Traditional chemotherapies are associated with cumulative toxicities over time, particularly myelosuppression, which is less of a concern with tarlatamab.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
September 18th 2022Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma
June 20th 2022A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.
